Evidence map›Paper›PMID 39471070›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Humoral Immunity Profiling to Pandemic and Bat-Derived Coronavirus Variants: A Geographical Comparison.

Parinaz Fathi, Andrea Lucia Alfonso, Christina Yek, Zoe Putman, Matthew Drew, Dominic Esposito, Irfan Zaidi, Sophana Chea, Sokna Ly, Rathanak Sath and 12 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Parinaz FathiSection on Immunoengineering, Biomedical Engineering and Technology Acceleration Center, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD, 20892, USA.ORCID 0000-0003-1639-5687
Andrea Lucia AlfonsoSection on Immunoengineering, Biomedical Engineering and Technology Acceleration Center, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD, 20892, USA.
Christina YekLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, MD, 20892, USA.
Zoe PutmanProtein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick, MD, 21701, USA.
Matthew DrewProtein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick, MD, 21701, USA.
Dominic EspositoProtein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick, MD, 21701, USA.
Irfan ZaidiLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, 20892, USA.
Sophana CheaInternational Center of Excellence in Research Cambodia, National Institute of Allergy and Infectious Diseases, Phnom Penh, 120801, Cambodia.
Sokna LyInternational Center of Excellence in Research Cambodia, National Institute of Allergy and Infectious Diseases, Phnom Penh, 120801, Cambodia.
Rathanak SathInternational Center of Excellence in Research Cambodia, National Institute of Allergy and Infectious Diseases, Phnom Penh, 120801, Cambodia.
Chanthap LonInternational Center of Excellence in Research Cambodia, National Institute of Allergy and Infectious Diseases, Phnom Penh, 120801, Cambodia.
Huch CheaNational Center for Parasitology, Entomology, and Malaria Control, Ministry of Health, Phnom Penh, 120801, Cambodia.
Rithea LeangNational Center for Parasitology, Entomology, and Malaria Control, Ministry of Health, Phnom Penh, 120801, Cambodia.
Rekol HuyNational Center for Parasitology, Entomology, and Malaria Control, Ministry of Health, Phnom Penh, 120801, Cambodia.
Sovann LyCambodian Center for Disease Control, Ministry of Health, Phnom Penh, 120407, Cambodia.
Heng SengCambodian Center for Disease Control, Ministry of Health, Phnom Penh, 120407, Cambodia.
Chee Wah TanProgramme for Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 169857, Singapore, Singapore.
Feng ZhuProgramme for Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 169857, Singapore, Singapore.
Lin-Fa WangProgramme for Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 169857, Singapore, Singapore.
Fabiano OliveiraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, MD, 20892, USA.
Kaitlyn SadtlerSection on Immunoengineering, Biomedical Engineering and Technology Acceleration Center, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD, 20892, USA.ORCID 0000-0003-2587-8330
Jessica ManningLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, MD, 20892, USA.

Funding

Intramural Research Programs of the National Institute of Biomedical Imaging and Bioengineering and the National Institute of Allergy and Infectious Diseases, National Institutes of HealthNational Medical Research Council COVID-19RF-003National Medical Research Council OFLCG19May-0034NIH HHS
6 · The paper itself

Abstract

Dynamic pathogen exposure may impact the immunological response to SARS-CoV-2 (SCV2). One potential explanation for the lack of severe SCV2-related morbidity and mortality in Southeast Asia is prior exposure to related betacoronaviruses. Recent discoveries of SCV2-related betacoronaviruses from horseshoe bats (Rhinolophus sinicus) in Thailand, Laos, and Cambodia suggest the potential for bat-to-human spillover exposures in the region. In this work, serum antibodies to protein constructs from SCV2 and a representative bat coronavirus isolated in Cambodia (RshSTT182) are measured in pre-pandemic Cambodian human sera using ELISA assays. Of 293 Cambodian samples tested (N = 131 with acute malaria, n = 162 with acute undifferentiated febrile illness), 32 (10.9%) are seropositive for SCV2 based on established Spike and receptor-binding domain (RBD) cutoffs. Within SCV2 seropositive samples, 16 (50%) have higher antibody levels to antigens from the representative virus RshSTT182 versus SCV2 antigens; competitive binding ELISA assays demonstrate inhibition of reactivity to SCV2 Spike after pre-incubation with RshSTT182 Spike. Surrogate virus neutralization tests demonstrate that 8/30 (26.7%) SCV2 ELISA positive pre-pandemic Cambodian samples have neutralizing activity against SCV2, while 14/30 (46.7%) have activity against other SCV2-related betacoronaviruses. These data suggest that exposure to related betacoronaviruses may elicit cross-reactive immunity to SCV2 prior to the global pandemic.

Indexed as

Antibodies, ViralChiropteraCOVID-19Immunity, HumoralSARS-CoV-2AdultAnimalsAntibodies, NeutralizingCambodiaEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedPandemicsAntibodies, NeutralizingAntibodies, Viralantibodiesbatsbetacoronavirusescross‐reactivitySARS‐CoV‐2

Identifiers

PMID39471070
PMCPMC11714182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.